Document Detail

Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
MedLine Citation:
PMID:  7682909     Owner:  NLM     Status:  MEDLINE    
Mifepristone is a potent oral antiprogestogen which acts at the level of the receptor, having a high affinity for the progesterone receptor. Most of the clinical trials have studied its efficacy in the termination of early pregnancy when used in conjunction with a low dosage of a prostaglandin analogue. In these studies, mifepristone 100 to 600mg administered as a single dose or over 3 or 4 days, 36 to 48 hours before a prostaglandin analogue given vaginally, intramuscularly or orally, induced complete abortion in about 95% of women. Used alone, mifepristone is an effective cervical priming agent prior to termination of first trimester pregnancy by vacuum aspiration, and facilitates termination of second trimester pregnancy by prostaglandin by reducing the interval between the start of prostaglandin treatment and termination, the cumulative prostaglandin dosage, and the adverse effects associated with these drugs. Mifepristone can also be used to induce labour in cases of intrauterine fetal death. Mifepristone has been shown to be an effective postcoital contraceptive with a likely emergency role, since its repeated use modifies the menstrual cycle. Pilot studies have been performed in unresectable meningioma and metastatic breast cancer, and in Cushing's syndrome. Mifepristone is generally well tolerated, and thus is an effective, appropriate, medical alternative to surgical termination of early pregnancy. It has as yet unexplored potential as a postcoital contraceptive and in oncology.
R N Brogden; K L Goa; D Faulds
Related Documents :
18509869 - The effect of gestational age on the outcome of second-trimester termination of pregnan...
3337789 - Pregnancy delays paracetamol absorption and gastric emptying in patients undergoing sur...
14692649 - Unilateral transverse arm defect with subterminal digital nubbins.
18624139 - Discrepancies in the laws on identifying foetal sex and terminating a pregnancy in india.
12798539 - A comparison of oral misoprostol with vaginal misoprostol administration in second-trim...
14526299 - A randomized comparison of two regimens of misoprostol for second-trimester pregnancy t...
11770579 - Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during tw...
7710299 - Cumulus removal and addition of follicular fluid possibly improves pregnancy rates with...
18241089 - Prediction of pre-eclampsia by uterine artery doppler imaging: relationship to gestatio...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  45     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1993 Mar 
Date Detail:
Created Date:  1993-05-26     Completed Date:  1993-05-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  384-409     Citation Subset:  IM    
Adis International Limited, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Contraceptives, Postcoital / pharmacokinetics,  pharmacology*
Mifepristone / adverse effects,  pharmacokinetics,  pharmacology*,  therapeutic use
Reg. No./Substance:
0/Contraceptives, Postcoital; 84371-65-3/Mifepristone
Erratum In:
Drugs 1993 Aug;46(2):268

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Drug treatment of resistant schizophrenia. Limitations and recommendations.
Next Document:  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential...